Navigation Links
Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
Date:11/7/2011

BOONTON, N.J., Nov. 7, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced today that management will report third quarter 2011 financial results before market open and host a conference call and live audio webcast on Wednesday, November 9, 2011 at 11 a.m., ET to discuss the results.

Interested participants and investors may access the conference call at 11 a.m., ET by dialing 800-259-0251 (U.S./Canada) or 617-614-3671 (international); participant code 29191227.  An audio webcast can be accessed by logging on to the Investors & Media section under the Events tab of the Unigene web site, http://www.unigene.com.

A telephonic replay of the call will be available for seven days beginning at 2 p.m., ET on November 9. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international); participant code 44127298.  The webcast replay will remain available in the Investors section of the Unigene Laboratories web site for 30 days.

About Unigene Laboratories, Inc.:

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
jthomas@unigene.com

Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020
jrando@tiberend.com / amielach@tiberend.com


'/>"/>
SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed ... a health care service center company based in ... in relationship management programs for leading pharmaceutical manufacturers and ... WRB will join Envoy Health Management, LLC ... manufacturers, biotech firms, and other service companies. Together, WRB ...
(Date:5/6/2017)... May 5, 2017  May is Stroke Awareness Month ... the most important methods to prevent a stroke: monitor ... for Disease Control and Prevention, undetected and uncontrolled hypertension ... Omron, the global leader in personal heart health technology, ... of heart attack and stroke and is advancing a ...
(Date:5/4/2017)... Inc. (" Fortuna "), a private, clinical-stage biotech company, ... for embryonic and fetal stem cells by using direct reprogramming ... announced today the launch of its Scientific Advisory ... Father Kevin FitzGerald , S.J., PhD; Col. (R) ... , PhD. "We are excited and honored to ...
Breaking Medicine Technology:
(Date:5/22/2017)... ... , ... Galena, Alaska, has a population of less than 500 people. But, ... targeted to build a nuclear plant by the TOSHIBA Corporation. , In “The Galena ... describes the journey to get power to his small town, off the electrical grid. ...
(Date:5/22/2017)... ... May 22, 2017 , ... OSF Ventures, ... investing in InsightRX, an early stage company in San Francisco that has developed ... Greatpoint Ventures Innovation Fund acted as the lead investor in the ...
(Date:5/21/2017)... ... 2017 , ... GetLinked® software continues to enhance ... systems. , Dozens of clubs using ABC Financial Services are now connected using ... their club’s accounting system , The latest implementation is Riverside Health Club ...
(Date:5/21/2017)... ... May 21, 2017 , ... For the ... cross-disciplinary group of scholars, policymakers, and activists wanting to address equity issues in ... is the third book from a recent series of from this conference. ...
(Date:5/21/2017)... ... , ... Following the tragic and widely publicized death of Rory Staunton, 12, ... hospitals follow a protocol to quickly identify and treat the condition. , The ... would have saved Rory or anyone else’s life. , Now, five years after ...
Breaking Medicine News(10 mins):